Abstract
1. Plasma concentrations of halofantrine (Hf) and its putative principal plasma metabolite desbutyl halofantrine (Hfm) have been measured in two separate studies after oral administration of the hydrochloride salt. 2. Six healthy male volunteers each received single oral doses of 250, 500 and 1000 mg administered after an overnight fast. A washout period of at least 6 weeks was allowed between each dose. A further 250 mg single oral dose was administered to the same six subjects in a fasting state and after a standardised fatty meal in a randomised study, again with a washout period of at least 6 weeks. 3. AUC and maximum plasma concentration (Cmax) for Hf increased in proportion to the dose from 250-500 mg. This increase was non-proportional when the dose was increased from 500 to 1000 mg. For Hfm, in the dose range 250-500 mg, AUC but not Cmax increased in proportion in the increase in dose size. The increase in these parameters was non-proportional when the dose was increased from 500 to 1000 mg. Time to reach peak concentrations for Hf and Hfm and the elimination half-life of Hf remained unchanged across the dosage range. 4. Following a fatty meal, Cmax for Hf was increased from 184 +/- 115 micrograms l-1 (fasting) to 1218 +/- 464 micrograms l-1 (fed). AUC for Hf was increased from 3.9 +/- 2.6 mg l-1 h (fasting) to 11.3 +/- 3.5 mg l-1 h following a fatty meal.(ABSTRACT TRUNCATED AT 250 WORDS)
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Boudreau E. F., Pang L. W., Dixon K. E., Webster H. K., Pavanand K., Tosingha L., Somutsakorn P., Canfield C. J. Malaria: treatment efficacy of halofantrine (WR 171,669) in initial field trials in Thailand. Bull World Health Organ. 1988;66(2):227–235. [PMC free article] [PubMed] [Google Scholar]
- Gilles H. M. The treatment and prophylaxis of malaria. Ann Trop Med Parasitol. 1987 Oct;81(5):607–617. doi: 10.1080/00034983.1987.11812162. [DOI] [PubMed] [Google Scholar]
- Horton R. J. Introduction of halofantrine for malaria treatment. Parasitol Today. 1988 Sep;4(9):238–239. doi: 10.1016/0169-4758(88)90136-6. [DOI] [PubMed] [Google Scholar]
- Milton K. A., Ward S. A., Edwards G. Determination of halofantrine and its principal metabolite desbutylhalofantrine in biological fluids by reversed-phase high-performance liquid chromatography. J Chromatogr. 1988 Dec 9;433:339–344. doi: 10.1016/s0378-4347(00)80618-0. [DOI] [PubMed] [Google Scholar]
- Münst G. J., Karlaganis G., Bircher J. Plasma concentrations of mebendazole during treatment of echinococcosis: preliminary results. Eur J Clin Pharmacol. 1980 May;17(5):375–378. doi: 10.1007/BF00558451. [DOI] [PubMed] [Google Scholar]
- Watkins W. M., Oloo J. A., Lury J. D., Mosoba M., Kariuki D., Mjomba M., Koech D. K., Gilles H. M. Efficacy of multiple-dose halofantrine in treatment of chloroquine-resistant falciparum malaria in children in Kenya. Lancet. 1988 Jul 30;2(8605):247–250. doi: 10.1016/s0140-6736(88)92538-x. [DOI] [PubMed] [Google Scholar]
- Welling P. G. Influence of food and diet on gastrointestinal drug absorption: a review. J Pharmacokinet Biopharm. 1977 Aug;5(4):291–334. doi: 10.1007/BF01061694. [DOI] [PubMed] [Google Scholar]
- White N. J. Clinical pharmacokinetics of antimalarial drugs. Clin Pharmacokinet. 1985 May-Jun;10(3):187–215. doi: 10.2165/00003088-198510030-00001. [DOI] [PubMed] [Google Scholar]
- Wirima J., Khoromana C., Molyneux M. E., Gilles H. M. Clinical trials with halofantrine hydrochloride in Malawi. Lancet. 1988 Jul 30;2(8605):250–252. doi: 10.1016/s0140-6736(88)92539-1. [DOI] [PubMed] [Google Scholar]